Table 1 Baseline characteristics of the patients per analysis in the sufentanil and remifentanil group
| Â | Induction of anaesthesia | Atropine administration | ||
|---|---|---|---|---|
Sufentanil (n = 30) | Remifentanil (n = 30) | Sufentanil (n = 20) | Remifentanil (n = 20) | |
Age (years) | 64 ± 8 | 67 ± 8 | 66 ± 9 | 70 ± 7 |
Sex, male | 23 | 23 | 18 | 16 |
Height (cm) | 174 ± 10 | 174 ± 11 | 175 ± 8 | 175 ± 11 |
Weight (kg) | 81 ± 16 | 78 ± 11 | 82 ± 14 | 83 ± 11 |
BMI (kg m− 2) | 27 ± 4 | 26 ± 3 | 27 ± 4 | 27 ± 3 |
Medical history | ||||
 Arterial hypertension | 20 | 21 | 13 | 15 |
 Peripheral vascular disease | 4 | 2 | 4 | 0 |
 Diabetes mellitus | 11 | 7 | 8 | 5 |
 Chronic obstructive pulmonary disease | 8 | 8 | 6 | 4 |
Relevant medication | ||||
 Beta blocking agents | 27 | 29 | 18 | 18 |
 Angiotensin receptor blockers | 7 | 4 | 6 | 1 |
 Angiotensin-converting enzyme inhibitors | 14 | 19 | 9 | 13 |